594 reports of this reaction
3.9% of all RANOLAZINE reports
#4 most reported adverse reaction
ANGINA PECTORIS is the #4 most commonly reported adverse reaction for RANOLAZINE, manufactured by A2A Integrated Pharmaceuticals. There are 594 FDA adverse event reports linking RANOLAZINE to ANGINA PECTORIS. This represents approximately 3.9% of all 15,363 adverse event reports for this drug.
Patients taking RANOLAZINE who experience angina pectoris should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANGINA PECTORIS is moderately reported among RANOLAZINE users, representing a notable but not dominant share of adverse events.
In addition to angina pectoris, the following adverse reactions have been reported for RANOLAZINE:
The following drugs have also been linked to angina pectoris in FDA adverse event reports:
ANGINA PECTORIS has been reported as an adverse event in 594 FDA reports for RANOLAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANGINA PECTORIS accounts for approximately 3.9% of all adverse event reports for RANOLAZINE, making it a notable side effect.
If you experience angina pectoris while taking RANOLAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.